SCHEMBL24596390

SCHEMBL24596390

Fc1ccccc1Nc1nc(C(F)(F)F)ccc1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.45
RAB9A P51151 2/20 0.37
MAPT P10636 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
LCK P06239 1/20 0.37
NPC1 O15118 1/20 0.37
HTT P42858 2/20 0.37
TSHR P16473 1/20 0.37
PTK2 Q05397 1/20 0.37
TAS2R14 Q9NYV8 2/20 0.36
LATS1 O95835 1/20 0.36
HDAC4 P56524 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
MAPK10 P53779 1/20 0.36
IGF1R P08069 1/20 0.35
AURKA O14965 1/20 0.35
LRRK2 Q5S007 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24596360 0.86 LMNA (0.36) LMNATSHRTAS2R14MAPK10IGF1R
SCHEMBL24596243 0.86 LMNA (0.41) LMNASMN1; SMN2TAS2R14HDAC4HDAC6
SCHEMBL24596297 0.85 EPHX2 (0.47) LMNAMAPTKDM4EMEN1KMT2A
SCHEMBL24596182 0.84 CCR4 (0.40) LMNARAB9AMAPTKMT2ASMN1; SMN2
SCHEMBL24596284 0.84 IGF1R (0.54) KDM4EKMT2ALCKTSHRPTK2
SCHEMBL24596326 0.83 TYK2 (0.46) LMNAMAPT
SCHEMBL24596209 0.80 CCR4 (0.44) LMNATSHRTAS2R14IGF1R
SCHEMBL24596349 0.80 CDK19 (0.46) LMNARAB9AMAPTKDM4EMEN1
SCHEMBL24596343 0.79 SYK (0.37) MAPTKDM4EMEN1KMT2ATSHR
SCHEMBL24596400 0.78 IGF1R (0.42) LMNAMAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) 2024-04-18 US disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
EP-4273146-A1 TRICYCLIC COMPOUND AND USE THEREOF Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) 2023-11-08 EP disclosed
CN-116670144-A Tricyclic compounds and uses thereof 南京再明医药有限公司 2023-08-29 CN disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed
WO-2022143864-A1 TRICYCLIC COMPOUND AND USE THEREOF 江苏先声药业有限公司 2022-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124454-A1 TRICYCLIC COMPOUND AND USE THEREOF MAT2A, MNAT1, KAT2A LMNA 293/4885RAB9A 1294/4885MAPT 466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.